Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer

2017 ◽  
Vol 7 (3) ◽  
pp. 173-182 ◽  
Author(s):  
Diego A.S. Toesca ◽  
Evan C. Osmundson ◽  
Rie von Eyben ◽  
Jenny L. Shaffer ◽  
Albert C. Koong ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Liver Cancer ◽  
Stereotactic Body Radiation Therapy ◽  
Primary Liver Cancer ◽  
Hepatic Function ◽  
Stereotactic Body Radiation

scholarly journals Comparison of stereotactic body radiation therapy versus fractionated radiation therapy for primary liver cancer with portal vein tumor thrombus

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Sujing Zhang ◽  
Li He ◽  
Changwen Bo ◽  
Shufang Yang ◽  
Yonghui An ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Liver Cancer ◽  
Portal Vein ◽  
Clinical Outcomes ◽  
Tumor Thrombus ◽  
Stereotactic Body Radiation Therapy ◽  
Primary Liver Cancer ◽  
Stereotactic Body Radiation ◽  
Fractionated Radiation Therapy ◽  
Fractionated Radiation

Abstract Background To compare the clinical outcomes of stereotactic body radiation therapy (SBRT) and fractionated radiation therapy (FRT) for primary liver cancer with portal vein tumor thrombus (PVTT). Methods This retrospective study included 36 patients who underwent SBRT and 36 patients who underwent FRT from August 2016 to June 2018. Patients were evaluated for short-term efficacy, long-term efficacy, AEs, and quality of life before and after treatment. Results With a median follow-up of 28.8 months (26–36 months), 27 patients survived in the SBRT group while 19 patients survived in the FRT group. The survival rate in the SBRT group was statistically higher than that of the FRT group after 6 months (80.56% vs. 58.33%; P = 0.041), 12 months (77.78% vs. 55.56%; P = 0.046) and 24 months 75.00% vs. 52.78%; P = 0.049). The median whole survival time of the SBRT group was 13.3 months (95% CI 12.83–13.97), which was statistically longer than 9.8 months in the FRT group (95% CI 8.83–10.97, P < 0.05) based on the Kaplan–Meier method. The SBRT group had better survival quality and fewer adverse events than the FRT group. Conclusion SBRT had better clinical outcomes than FRT for primary liver cancer with PVTT.

Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

2020 ◽  
Vol 04 (02) ◽  
pp. 187-194
Author(s):  
Shauna R. Campbell ◽  
Timothy D. Smile ◽  
Sarah M.C. Sittenfeld ◽  
Kevin L. Stephans
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiation Therapy ◽  
Stereotactic Body Radiation Therapy ◽  
Primary Liver Cancer ◽  
Effective Treatment Option ◽  
Stereotactic Body Radiation ◽  
Common Cancer ◽  
Clinical Presentations ◽  
Liver Cancers ◽  
Bridging To Transplant

AbstractPrimary liver cancer is the seventh most common cancer worldwide and is the second leading cause of cancer-related death. Hepatocellular carcinoma (HCC) accounts for three-quarters of primary liver cancers and less than a third of patients present with curable disease. Liver-directed therapy is essential for the treatment of patients with unresectable HCC and the advancement of stereotactic body radiation therapy (SBRT) has made radiation a safe and effective treatment option in a range of clinical presentations. In this review, we discuss the technical aspects of SBRT and the general approach to treatment of HCC. We explore the use of SBRT for bridging to transplant, downstaging, and the treatment of large tumors and portal vein tumor thrombus. Although there is limited high-quality randomized data, we review the evidence comparing SBRT with other liver-directed therapies and explore areas for future investigation.

The impact of respiratory motion and treatment technique on stereotactic body radiation therapy for liver cancer

2008 ◽  
Vol 35 (4) ◽  
pp. 1440-1451 ◽  
Author(s):  
Q. Jackie Wu ◽  
Danthai Thongphiew ◽  
Zhiheng Wang ◽  
Vira Chankong ◽  
Fang-Fang Yin
Keyword(s):  
Radiation Therapy ◽  
Liver Cancer ◽  
Respiratory Motion ◽  
Stereotactic Body Radiation Therapy ◽  
Treatment Technique ◽  
Stereotactic Body Radiation ◽  
The Impact

scholarly journals Screening of prognostic biomarkers for Stereotactic Body Radiation Therapy in liver cancer

2020 ◽  
Author(s):  
Zhenzhen Liang ◽  
Hongbin Sun ◽  
Binbin Yu ◽  
Xueyuan Zhang ◽  
Xinxin Fu ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Liver Cancer ◽  
Cancer Patients ◽  
High Throughput ◽  
High Throughput Sequencing ◽  
Stereotactic Body Radiation Therapy ◽  
Test Group ◽  
Prognostic Biomarkers ◽  
Optimal Threshold ◽  
Stereotactic Body Radiation

Abstract So far there are still no effective immediate-early markers for assessing the efficacy of Stereotactic Body Radiation Therapy (SBRT). To find effective biomarkers for accurate assessment of the efficacy of SBRT in patients with liver cancer. Patients with liver cancer were included at Ruikang Hospital affiliated to Guangxi Medical University from January 2012 to December 2018. Follow-up was conducted, clinical information and blood samples (before SBRT, before discharge and 2 months after SBRT) were collected. mRNAs profiles were detected by high-throughput sequencing, followed by qPCR verification. The commonly-used serum biomarkers such as AFP, CEA and CA125 shown low prognostic value in distinguishing survival group and death group, indicated by low AUC (less than 0.7) and Yoden indexes (less than 0.5). Based on high-throughput sequencing of test group and qPCR detection of another verification group, we found 16 up-regulated and 12 down-regulated genes after SBRT. Among them, ADIPOR1 and EPB42 showed significantly different between effective and ineffective group after SBRT, ROC suggested that based on the optimal threshold of 0.5838, ADIPOR1 shown a sensitivity of 100% and a specificity of 83.33% to distinguish effective from ineffective group. Similarly, EPB42 had a sensitivity of 75% and a specificity of 100% at the optimal threshold of 1.3817. Thus, ADIPOR1 and EPB42 in whole blood are promising candidates to act as prognostic biomarkers for predication of SBRT outcomes in liver cancer patients.

Sign in / Sign up

Export Citation Format

Share Document